Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 3/20 | 0.31 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536826 | 0.82 | L3MBTL1 (0.50) | HTR6ALDH1A1 | |
| SCHEMBL13579554 | 0.72 | — | — | |
| SCHEMBL19145739 | 0.68 | RAPGEF4 (0.43) | HTR6PIK3C3OPRM1OPRL1 | |
| SCHEMBL12032364 | 0.68 | HTR6 (0.35) | HTR6DRD2PIK3C3NR3C1 | |
| SCHEMBL12032358 | 0.66 | HTR6 (0.33) | HTR6PIK3C3 | |
| SCHEMBL12032360 | 0.66 | HTR6 (0.33) | HTR6PIK3C3 | |
| SCHEMBL12032356 | 0.65 | HTR6 (0.35) | HTR6DRD2PIK3C3ATRATRIP | |
| SCHEMBL17711599 | 0.65 | SLC22A12 (0.43) | HTR6DRD2PIK3C3ATRATRIP | |
| SCHEMBL17160481 | 0.65 | HTR6 (0.41) | HTR6DRD2PIK3C3ATRATRIP | |
| SCHEMBL20388883 | 0.65 | OPRM1 (0.39) | HTR6DRD2PIK3C3ALDH1A1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-9365579-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-8962629-B2 | Tricyclic compounds | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20090312338-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312338-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | HTR6 1737/4885DRD2 1941/4885PIK3C3 729/4885 |
| US-20160326181-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | HTR6 1737/4885DRD2 1941/4885PIK3C3 729/4885 |
| US-20150210708-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | HTR6 1737/4885DRD2 1941/4885PIK3C3 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.